Queensland Medi-Aesthetic Compliance Checklist 2026

Since September 2025, the medi-aesthetic clinic compliance Queensland guidelines have experienced a long-awaited update, and this is a business-critical risk area for several reasons. The current regulatory expectations focus heavily on clinical governance, Schedule 4 medicine handling (prescription-only medicines and injectables), and stricter advertising standards, as well as stricter guidelines for enhanced consent requirements.

In practice, these updated AHPRA guidance reinforce existing obligations under National Law and change how treatments are carried out, who can prescribe medicine, and overall safety throughout the patients’ journey, and it is important to review these updates to stay compliant. Our clear aesthetic clinic compliance Queensland guide is for medi-aesthetic clinic owners, practice managers, and supervising physicians, who can follow our detailed compliance checklist to easily conduct compliance audits. By ensuring consistent compliance, you will not only safeguard patient care but also enhance loyalty and retention, leading to increased business longevity.

This downloadable checklist will provide an easy-to-digest, plain-English breakdown of what is required to stay compliant with these recent regulations by AHPRA (The Australian Health Practitioner Regulation Agency), which came into effect in early September 2025. By referring to the medi-aesthetic clinic compliance checklist 2026, practitioners can review their medi-aesthetic business annually or quarterly to ensure they are staying compliant with Queensland aesthetic clinic regulations.

Queensland Medi-Aesthetic Compliance in 2026

The good news is that this guide and accompanying checklist are designed to translate often complicated and confusing legal jargon into clear, concise information so that medi-aesthetic clinic owners can fully understand how to adapt to the medi-aesthetic clinic compliance Queensland guidelines. Rather than a legal interpretation document, it focuses on what clinics need to actively manage, review, and document to remain compliant in 2026.

In practical terms, medical aesthetics compliance Australia revolves around five key areas, which include clinical governance, medicines and injectables, staff roles and delegation, patient documentation, and advertising guidelines.

Below, we will focus on each of these key areas, which are the areas that tend to be reviewed during audits, complaints, investigations, and insurer reviews. These form the basis of the Queensland clinic compliance requirements checklist.

Clinical governance + oversight – Who is responsible and how are decisions made?

Put simply, clinical governance and oversight cover how the clinic is structured, from a clinical accountability perspective. This allows clinic owners and practitioners to identify the supervising practitioner, review how clinic decisions are overseen, and whether these governance structures are working in reality rather than just in theory (or just documented).

This is crucial since regulatory bodies expect clinics to establish a clear clinical governance and oversight structure to ensure patient safety and accountability.

Medicines & injectables (Schedule 4) – How are injectables ordered and stored?

This refers to Schedule 4 medicines and injectables, which in Australia are prescription-only drugs that must be prescribed by an authorised health professional. Since cosmetic injectables fall under this category, this section focuses on the storage, ordering, stock control, waste tracking, and usage documentation.

There are several bodies involved in the oversight of Schedule 4 medicines in Queensland, including the TGA (Therapeutic Goods Administration), who regulate therapeutic medicines at a national level through the Therapeutic Goods Act 1989, and Queensland Health, who regulate the possession, storage, prescription, and handling of these medicines through the Medicines and Poisons framework.

Staff roles and delegation – Who can do what, clinically?

As the section title suggests, this refers to the exact role of each staff member and who is allowed to do what, and under what level of supervision. This includes Registered Nurse involvement in cosmetic injectables, delegation frameworks, and prescribing pathways.

Under the medical aesthetics clinic legal requirements in Queensland, one of the most common compliance failures is poorly documented or undocumented delegation.

Patient documentation & consent – Records and consent requirements

Patient documentation and consent covers how clinics obtain information from patients as well as record and store confidential clinical notes. These can include anything from client consultation forms and aftercare instructions to treatment explanations and risk assessments.

In 2026, expectations are less about having these consent forms, but rather it is more about the ability to demonstrate that patient consent is informed, treatment-specific, and properly documented, which makes it easier to audit.

Advertising & claims (AHPRA + TGA) – What clinics can (and cannot) say when marketing

Today, medi-aesthetic clinics rely heavily on marketing, and staying compliant in Queensland means understanding what you can and cannot say when advertising. This section focuses heavily on how clinics communicate with patients or potential patients across social media, websites, and other promotional materials.

This zooms in on the AHPRA advertising guidelines, cosmetic injectables 2025/2026, and TGA advertising rules, cosmetic injectables Australia, that are in place. It is particularly focused on avoiding misleading claims, guaranteed outcomes, managing testimonials, and ensuring accuracy in before-and-after content. Clinics are expected to have controlled, reviewable processes for all published content.

Plain-English Summary of the AHPRA September 2025 Guidance

Rather than thinking of the AHPRA medi-aesthetic guidelines as a completely new regulatory framework, see it more as a reinforcement of the tightening of rules that were already put in place. In September 2025, the AHPRA introduced much stricter guidelines that zoom in on specific areas to ensure patient safety, accountability, and clinical oversight, amongst other aspects.

What you need to know is that now medi-aesthetic clinics in Queensland are being assessed more explicitly through evidence of frameworks, governance, and accountability, rather than just the existence of these aspects. While many medi-aesthetic clinics in Queensland may already have implemented these systems to support compliance, under current expectations, the focus is shifting towards how these systems are consistently being applied, so clinic owners across the state should take this opportunity to review and audit their current processes.

In other words, as it stands, Queensland aesthetic clinic regulations require clinics to demonstrate how care is supervised, how S4 medicines are prescribed, and how patients are protected at each stage of treatment.

The intent of AHPRA’s 2025 update

Above all else, the key intent of the updated regulations is to safeguard patient safety by targeting unsafe practices and misleading advertising, etc. These guidelines will ensure patients benefit from additional protections when undergoing cosmetic procedures, but there are also great benefits for businesses, too. By staying compliant and ensuring proper systems are in place, patients build trust, retention grows, and businesses flourish.

‘Patient safety must come first,’ – Ahpra CEO Justin Untersteiner.

Accountability also plays a huge part in the stricter medi-aesthetic regulations in Queensland. Patient safety comes down to clinical oversight, which ensures that decision-making is clearly owned, properly supervised, and documented in the right way. Additionally, where Schedule 4 medicine (prescription only) or injectables are used, the guidance reinforces that this should be treated as a medical treatment with proper supervision. All in all, the stricter rules are in place to ensure that patients can feel confident and well-informed when opting into a cosmetic procedure.

What AHPRA expects clinics to be able to evidence

What is crucial to note is that the stricter Queensland aesthetic clinic regulations are focusing on evidence, and clinic owners need to ensure that they do not just have systems in place, but that they can show how it works consistently and effectively business-wide. This is important to understand since legal requirements can often be confusing and complex; however, many medi-aesthetic clinic owners may already have appropriate processes in place to support compliance.

The key step in 2026 is therefore not necessarily to start from scratch, but to formally audit existing workflows, close any documentation gaps, and ensure there is clear, consistent evidence to demonstrate how compliance is being achieved in practice. As outlined in the stricter guidelines, implemented in September 2025, AHPRA expects clinic owners to demonstrate:

Clear clinical oversight structure: Under this section, AHPRA requires clinics to be able to demonstrate a defined and consistent clinical governance structure. This must include an identifiable, registered, and appropriately trained practitioner who is responsible for oversight of cosmetic treatments. This structure should show how clinical decisions are supervised, escalated, and reviewed in practice, particularly for procedures involving S4 (Schedule 4 prescription-only) medicines.
Competence and training documentation: Under the revised requirements in September 2025, the AHPRA focuses on competence and training documentation to ensure patients are in safe hands. According to the AHPRA guidelines, “all registered health practitioners are required to work within the limits of their skills, training, and experience.” However, they stressed that “the level and type of education and training required to perform a cosmetic procedure competently and safely may vary significantly”. It is also necessary to have well-documented evidence of all training from initial to ongoing training.
Safe prescribing pathways: Since cosmetic injectables fall under the Schedule 4 category of prescription-only medications, prescribing arrangements must be clearly documented. Clinics need to be able to demonstrate evidence of who is authorised to prescribe, how these decisions are made, and how they link to treatment plans for patients.
Honest advertising and consent standards: Under the guidelines, the AHPRA recognised the need to implement stricter advertising rules, stating that advertisements cannot use AI-generated or heavily edited images, must include a warning that results may vary to demonstrate transparency, and a ban on using testimonials from social media influencers was tightened.

Regarding stricter advertising guidelines, Medical Board of Australia Chair, Dr Susan O’Dwyer, said, “Unfortunately, exploitative advertising has increased as fast as patient demand. We have tightened the rules to support patients, so they can make safe and informed choices.”

Common compliance gaps AHPRA is trying to eliminate

Even well-run clinics can develop compliance gaps over time. As businesses evolve, processes are often adapted, responsibilities shift, and informal ways of working can gradually replace protocols without anyone noticing.

Before conducting audits, it is important to understand the common compliance gap, which you can refer to when reviewing your business systems and protocols. What clinic owners should know when it comes to medical aesthetics compliance in Australia is that there are several recurring areas where compliance gaps can be found, which can range from poor advertising to weak documentation.

Below, we will outline the most common compliance gaps that AHPRA is trying to eliminate through its stricter regulations.

“Paper medical director” risk: A clinic may have a medical director on paper, but the question is, “How involved are they in the actual day-to-day activities and procedures?” This is one of the most common pitfalls regarding medi-aesthetic compliance, and if a regulator asked who is responsible for overseeing treatments, managing complications, or reviewing clinical decisions, the answer should be clear and backed up by clear evidence. Under the stricter AHPRA regulations, clinic owners need to demonstrate clear evidence across the board, including clinical oversight.
Weak consent/documentation: Another common compliance gap involves weak consent and documentation. It is now not enough to be in possession of patient consent forms; the AHPRA is seeking clear evidence that these forms contain specific details of what actually happened during the consultation. These forms need to show that patients were informed about the treatment procedure, possible risks, aftercare, and alternative available treatments. These consent forms should have all relevant information, should a patient raise a concern or complaint down the line.
Confusing role boundaries (clinical vs admin): It can happen that as clinics become busier, staff take on other roles or responsibilities. However, one of the main compliance gaps is specific staff roles, which they are trained to perform. Over time, this can create a level of confusion among colleagues, but AHPRA needs clinic owners to demonstrate who is responsible for certain tasks and to determine what level of authority each staff member has. Additionally, it is vital to know who can give information to patients and when a situation needs to be brought to a supervisor’s attention.
Marketing that implies outcomes/guarantees: As we have mentioned, advertising is a pivotal part of the medi-aesthetic industry, and Queensland is no exception. AHPRA recognised that stricter TGA advertising guidelines needed to be implemented to protect patients from unrealistic expectations due to advertising. These new requirements developed by the National Boards mean that information needs to be balanced and accurate, describe and show realistic results, and there is a ban on testimonials and the use of social media influencers.

Queensland cosmetic injectables compliance (Schedule 4 medicines) — the practical reality

Although advertising and consent requirements often receive the most attention, many compliance issues in medi-aesthetic clinics occur from the day-to-day handling of Schedule 4 prescription-only medicines and injectables. In Queensland, cosmetic injectables such as botulinum toxin and dermal fillers are classified as Schedule 4 (prescription-only) medicines.

The Medicines and Poisons Act 2019 and the Medicines and Poisons Regulation 2021 regulate the handling of these cosmetic injectables, from ordering and storage to supply and administration. This means that clinics must ensure that prescription-only medicines are ordered, stored, accessed, and documented appropriately throughout their lifecycle. In reality, this is where many clinics can encounter difficulties, particularly as clinics grow and responsibilities become shared across multiple team members. Even if clinics adhere to all other requirements laid out by the AHPRA, the handling of these tightly controlled products is what Queensland clinics must get right operationally.

The Queensland cosmetic injectables regulatory problem clinics run into

In practice, compliance gaps are not always related to the treatment itself but rather the storage and handling of these prescription-only medicines. This is where some medi-aesthetic clinics can fall short, making this a pivotal area to review and audit, in order to stay compliant. Queensland Health guidance places clear expectations on lawful supply chains, storage, and appropriate control of Schedule 4 medicines within approved business arrangements.

Important factors relating to the handling of these controlled Schedule 4 substances include:

Stock control: Stock must be controlled so that all S4 products and substances can be accounted for at all times. To adhere to the regulations, clinics need to be able to show what S4 products have been received, what have been used, and what remains in stock, including batch numbers and expiry dates. This is required to maintain traceability of prescription medicines.
Ordering: When it comes to ordering, it is important to note that only authorised practitioners can purchase S4 substances, i.e., a medical practitioner or Nurse Practitioner can only purchase cosmetic injectables for use in a cosmetic clinic. Queensland Health specifically states that other staff cannot place orders or purchase these products on behalf of the clinic. Additionally, they state that when ordering, “standing orders cannot be used for the administration of cosmetic injectables to patients”. Queensland Health guidance states that standing orders are not an appropriate mechanism for administering cosmetic injectables in beauty treatment or cosmetic clinic settings.
Custody: Queensland Health requires that cosmetic injectables remain under the appropriate custody of authorised practitioners within an approved business model, which means that medicines cannot be left unmanaged, shared, or accessible outside of defined governance arrangements. It is also worth noting that custody applies across the entire lifecycle of the medicine, including ordering, receipt, storage, administration, and disposal.
Who is authorised to handle what: Queensland cosmetic injectables regulations state that clinics must be able to clearly identify and define who is authorised to handle or access the S4 medicines in practice. Any unclear role boundaries between clinical and non-clinical staff are a common source of compliance risk.

Schedule 4 medicines: custody, ordering, storage, and documentation checklist.

In Queensland, medicines commonly used in cosmetic clinics, such as dermal fillers and injectables, fall under the category of Schedule 4 or S4, which means they are heavily regulated and tightly controlled. This comes down to who is allowed to order, store, and administer them, among other factors.

Ordering authority: According to Queensland Health’s cosmetic injectables rules, only qualified medical practitioners or Nurse Practitioners can order S4 products. This means that no other staff member is permitted to order on behalf of the clinic.
Receiving stock process: It is important to get familiar with the receiving process for S4 products, which includes checking and recording key details, including product type, quantity, batch numbers, and expiry dates. This ensures traceability from the point of delivery and confirms that the stock received matches what was lawfully ordered. This should all be documented and within easy reach when needed.
Storage requirements + access control: Under the Schedule 4 cosmetic injectables Queensland compliance, it is stated that in a shared clinic, a medicine store establisher (in writing only) must be appointed. This must be an appropriately qualified practitioner who is authorised to possess and administer these substances (a medical practitioner, Nurse Practitioner, or registered nurse). The regulation states that “the medicine store establisher must take all reasonable steps to ensure the medicine store is established and maintained in a way that keeps the medicines in the store in accordance with the manufacturer’s conditions for the medicines”. Access to this area is also within their control, and they need to determine a suitable storage area that cannot be easily accessed by the public or unauthorised people.
Stock reconciliation and wastage logs: Just as orders are to be documented, clinics must maintain accurate records showing how medicines move through the business, including what has been used, what remains, and what has expired or been discarded. Regular reconciliation between purchased stock and used stock is required to ensure full traceability of all Schedule 4 medicines. Wastage records form part of this accountability and must clearly document any expired, damaged, or unused products.
Incident process (lost stock, temperature excursion): The cosmetic injectables clinic compliance checklist Queensland also focuses on the incident process, which relates to any issues with the S4 products. This could be the loss of a product, damage to a product, or missing stock, all of which need to be recorded and investigated.

These incident records are necessary to demonstrate how the clinic maintained or restored compliance with Queensland Health expectations for safe handling of Schedule 4 medicines.

RN & Injector Role Clarity in Queensland

One of the fundamental aspects of running a medi-aesthetic clinic in Queensland is understanding who is authorised to perform specific duties. This has become increasingly important following the updated AHPRA guidelines in September 2025, meaning clinic owners should pay close attention to who can prescribe, store, order, and administer cosmetic injectables.

These guidelines reinforced the need for clearer clinic accounbtability, appropriate supervision and well defined clinical responsibilities, which together ensure overall patient safety. Understanding the RN cosmetic injectables Queensland rules is not just about determining who can administer these treatments, but it also involves understanding who can prescribe medicines, who can purchase and hold stock, what level of supervision is required, and how clinical decisions are documented and communicated throughout the patient journey.

RN cosmetic injectables Queensland rules

In cosmetic clinic settings, Registered Nurses are generally not authorised to order or purchase Schedule 4 cosmetic injectables, as this authority is restricted to prescribing practitioners only. To put it simply, RNs cannot independently order or purchase Schedule 4 cosmetic injectables under Queensland Medicines and Poisons legislation and associated practice requirements. This is the role of a doctor or Nurse Practitioner who is classified as an authorised prescriber, and can prescribe S4 medicines where clinically appropriate.

However, RNs can be involved in the administering of these substances, as long as they are properly trained and acting under a lawful prescription and within their professional scope of practice. Registered nurses are not authorised to independently prescribe or purchase Schedule 4 cosmetic injectables for a cosmetic clinic. This distinction is one of the most important areas of aesthetic clinic compliance that Queensland clinic owners should understand.

What clinics often assume vs what is permitted: Since the guidelines have become stricter, there has been some confusion around the role of RNs when it comes to cosmetic injectables. A common misconception is that RNs can operate independently once they are fully trained; professional experience or training does not override the law, which restricts this. Queensland Health guidance indicates that “RNs are authorised under the MPMR to buy medicines listed in the Extended Practice Authority called ‘Registered Nurses’; however, this does not include S4 medicines used for beauty treatment/cosmetic businesses/clinics”. Instead, purchasing authority remains with authorised prescribers.
Where clinics need explicit protocols and supervision: To support compliance, clinics need to have well-documented protocols in place, which describe the prescribing process, treatment delegations, supervision responsibilities, and escalation procedures. All staff should be aware of the roles and responsibilities of their colleagues and themselves, to ensure greater patient care and accountability.

Example of non-compliance in Queensland

Recent regulatory action in Queensland shone a light on the importance of clear prescribing pathways, accurate documentation, and adherence to professional obligations when providing cosmetic injectables. In 2026, it was reported that a Queensland practitioner was sanctioned after a tribunal identified multiple breaches of the RN cosmetic injectables Queensland rules relating to prescribing and administration requirements, demonstrating the ongoing regulatory focus on patient safety and accountability.

Competency, training records, and supervision checklist

Initial training evidence: To comply with aesthetic clinic compliance in Queensland, clinics should maintain clear training records, qualifications, and proof of registration, which can easily be sourced if audited. This should include cosmetic injectables training as well as onboarding assessments for all staff who are involved in
Device/product-specific competency: This relates to specific injectable products for which practitioners should be trained to use. Clinics should maintain clear evidence that competency has been assessed and documented for those specific treatments. These should be updated regularly as training evolves or during the onboarding of new staff.
Refresher training cadence: Competency should not be treated as a one-time occurrence. Instead, clinics should periodically review training records and identify opportunities for continued professional development, refresher education, or updates when regulations or clinical practices change. This is highly important in the case of high-risk cosmetic treatments, to ensure patient care is at the forefront.
Supervision requirements documented: Clinics should be able to clearly show who provides clinical oversight, when supervision occurs, and how practitioners access support when required. Maintaining documented supervision arrangements can help demonstrate accountability and support compliance with both professional and regulatory expectations.

Patient Consultations, Consent, and Documentation

Consultation workflow checklist

Consultation documentation and patient record keeping are crucial in a medi-aesthetic clinic setting, especially since many complaints, reviews, and investigations rely heavily on what information was gathered before, during, and after a treatment.

In practice, many medi-aesthetic clinics follow the patient documentation process, but to stay compliant, this should be carefully reviewed to ensure it is a structured system that follows the patient journey in detail. Since the aim of the updated AHPRA guidelines revolves around future-proofing patient safety, medi-aesthetic clinics need to review and verify the safety steps they implement for patients.

Below are some of the key areas to review to stay compliant.

Patient suitability and screening: Under evolving medical aesthetics clinic legal requirements in Queensland, practitioners must ensure that patients have been carefully screened, are well informed, and are suitable for the specific treatment. This can be viewed as the start of the client’s journey when the patient’s medical history should be obtained, contraindications and current medications should be reviewed, and other factors that may affect the treatment should be documented in detail.
Risk disclosure and expectations: As part of the patient journey, potential risks should be carefully explained in a clear and detailed way. Patients’ expectations should be established to determine whether the treatment is clinically appropriate or not. Apart from risks, side effects, limitations, and recovery expectations should be discussed. This is also when alternative treatments should be discussed if the original treatment is deemed unsuitable or not what the client expected. A well-documented suitability assessment is not only compliant but also minimises risks and ensures that the patient feels confident in their decision.
Consent capture and versioning: Before the said treatment takes place, it is the responsibility of the clinic to ensure patients have given informed consent for the treatment they are receiving. Clinics should keep a record of the date and time when consent was obtained, as well as ensuring that the right consultation form was used. In the case where consultation forms have been updated, clinics need to make sure that the latest version is being used. It is good practice to document what was discussed during this consultation, so there is a clear record of what information was shared before the treatment.
Aftercare instructions and follow-up documentation: It is important to note that consultation documentation does not end after the treatment; in fact, it is a vital part of patient safety, which AHPRA is focusing on, to ensure patients are aware of the aftercare protocol. Patients should receive detailed aftercare instructions that explain the expected recovery time as well as potential warning signs that they should be aware of.

Practitioners should allow time for patients to ask any questions or to clarify anything they are unsure of, especially in the case of complex instructions. Follow-up interactions, complications, and post-treatment advice should be documented at this stage and recorded with the patient’s file.

Record-keeping and audit readiness checklist

Medi-aesthetic clinic owners should remember that record-keeping forms the backbone of any Queensland clinic compliance requirements checklist. If a clinic is unable to easily retrieve and demonstrate clear record-keeping, it may struggle to evidence compliance where appropriate care was provided.

Below are a few areas that medi-aesthetic clinic owners and practitioners should review.

Minimum documentation standards: As a rule of thumb, patient records should be able to demonstrate the patient’s journey from start to finish. Record keeping is no longer a one-page signed form; instead, the patient file needs to be clear, detailed, and consistently updated. At a minimum, clinics should be able to evidence patient assessments, consultation notes, treatment plans, aftercare discussions, and follow-up communications, as well as complications during the procedure.
Secure storage/access controls: Patient records provide sensitive and personal information that should be mindfully and securely stored, with appropriate access controls in place. As part of the Queensland clinic compliance requirements checklist, clinics should regularly review who can access these clinical records and ensure that staff only have access to information necessary for their role. Whether clinics decide to store their files digitally or on paper, documentation should maintain confidentiality, integrity, and protection against unauthorised access.
Retention approach and internal audits: Regularly verifying whether records remain complete, accurate, and accessible is important to remember when staying compliant. Keeping patient records is not just about obtaining and storing information; clinics should have a clear process for how long records are to be kept, where they are stored, and who can access them. Regular internal audits can help stay on top of things by reviewing this process.

This can help identify missing information or incomplete documentation, which can demonstrate a record-keeping system that needs to be adjusted. It is advised to conduct audits quarterly or annually, to ensure that records are not only up to date, but also that they are easy to access in the event of an investigation, complaint, or clinic review. Records should ultimately provide a clear picture of the client’s journey from consultation and consent to treatment and aftercare.

Advertising Compliance in 2026

Advertising is one of the key compliance risk areas for medi-aesthetic clinics. Compared to other aspects such as record-keeping or clinical oversight, marketing is an outward-facing aspect of the business that can easily be reviewed by regulators, professional boards, as well as competitors and patients.

Under the updated AHPRA and TGA advertising rules for cosmetic injectables in Australia in September 2025, there are now strict rules on how cosmetic injectables can be advertised. Stricter advertising guidelines are seen as another crucial way to safeguard patient safety and to prevent unrealistic expectations, misinformation, and false advertisements.

AHPRA advertising guidelines cosmetic injectables 2025/2026 — what clinics must stop doing

Under the AHPRA advertising guidelines, Cosmetic Injectables 2025 2026, there is a strong emphasis on patient protection and informed decision-making. What this means in practical terms is that clinics should avoid advertising practices that create unrealistic expectations, minimise risk, or encourage impulsive decisions, i.e., promotions or dramatic before and after images.

Common compliance risks include:

Making claims that imply permanent or guaranteed results
Suggesting treatments are risk-free or suitable for everyone
Using before and after pictures that are edited.
Using wording that exaggerates likely outcomes
Publishing content that may mislead patients about benefits or treatment expectations.
Offering promotions or incentives to entice bookings
Using influencer or patient testimonials/reviews that refer to results or outcomes

TGA advertising rules for cosmetic injectables in Australia

The TGA (Therapeutic Goods Administration) regulates the advertising of therapeutic goods in Australia, including Schedule 4 medicines. This means that medi-aesthetics clinics must be extra careful when referencing cosmetic injectables across the web, social media channels, digital advertising campaigns, and other promotional materials.

Instead of making claims about the effectiveness of a specific product, clinics should aim to educate and inform potential clients about prescription-only medicines. Content should avoid stating that a particular injectable will achieve guaranteed results or that it is suitable for all patients. As a general rule of thumb, it is best to ensure any marketing content is seen as educational and that its purpose is to inform and not persuade.

Claims discipline: avoid efficacy promises, use balanced information: One of the best and simplest ways to reduce advertising risk is to adopt a disciplined approach to claims. When it comes to marketing, any marketing materials used should accurately reflect what treatments can and cannot achieve. They should also draw attention to the fact that results vary between individuals to avoid false expectations. Statements that imply certainty, perfection, or guaranteed outcomes can create compliance risks, particularly when they are not supported by evidence, so it is advised to be extra careful when creating materials for a marketing strategy. By showcasing balanced information, this helps patients make informed decisions and demonstrates that the clinic is prioritising patient welfare over promotional messaging.
Approval workflows: who signs off, where it’s stored: Many advertising compliance issues arise when content is published without formal review. Clinics should establish a formal review process, which outlines who is responsible for signing off on marketing materials, etc.

Below are some factors to consider regarding approval workflows:

Whose role is it to review content before publishing?
Who has the authority to approve marketing material?
Where should approved client documentation be stored?
How are changes updated and tracked on an ongoing basis?

Having a specific system in place demonstrates clinical governance and oversight regarding advertising and is one of the key components of the AHPRA updates. Now more than ever, the focus is on consistency, clinical governance, and patient safety, so reviewing your advertising processes and strategy is essential to stay compliant.

Advertising compliance checklist

Advertising for cosmetic injectables is regulated by National Law across Australia, and the guidelines apply to all forms of public advertising, from social media and websites to Google ads and email marketing. Under these rules, advertisements should not be misleading, must not create unrealistic expectations, and should inform rather than persuade.

Clinic owners and those signing off on marketing material need to ensure that the content is educational and is not created in a way that encourages demand. Clinics are responsible for all content and marketing material that they publish or control/

Below are the core advertising compliance controls clinics use to ensure marketing content remains accurate, consistent, and aligned with AHPRA and TGA requirements

Claim substantiation file: The claim substantiation file is a clinic record that supports any claims made in advertising or marketing materials. This can include treatment outcomes and benefits, and helps to ensure that nothing is being advertised without the facts to back it up.
Content review cadence: This is a set schedule that clinics should use to consistently review and monitor marketing content. By doing this regularly, it avoids leaving outdated or perhaps incorrect information online.
Staff posting policy: This is a simple set of rules set out by the clinic to ensure staff are staying compliant by outlining what they can and cannot post online when representing the clinic. By ensuring all staff are following the same rules, all content will follow the same advertising standards and therefore stay compliant across the board.
Handling testimonials/reviews policy: This refers to patient testimonials and how they are handled, so they are staying compliant by not referring to outcomes or results. It helps to ensure that feedback is not presented as advertising that guarantees results.

FAQs

What are the core Queensland aesthetic clinic regulations that clinics must follow in 2026?

It is worth noting that there is no single set of regulations that governs medi-aesthetic clinics in Queensland. Instead, clinics must comply with a combination of Queensland medicines legislation regulated by Queensland Health, AHPRA professional standards, and TGA advertising requirements.

Together, these bodies regulate various aspects of the industry, including how S4 cosmetic injectables are prescribed, purchased, stored, and administered, and how cosmetic services can and cannot be advertised to the public. For clinic owners, the key compliance areas in 2026 include clinical governance, medicines management, patient consent and record-keeping, staff competency and supervision, and advertising compliance. These areas reflect the currency expectations across the AHPRA guidance, which was updated in September 2025.

What changed in the AHPRA September 2025 guidance for cosmetic practice?

It is important to note that the AHPRA guidelines, which came into effect in September 2025, were put in place to safeguard patient safety. While no new legislation was established, a new strict set of rules was implemented to strengthen the existing laws, focusing on areas such as advertising, informed consent, patient safety, and clinical governance.

These new guidelines focused heavily on the ways medi-aesthetic clinics can and cannot advertise, i.e., no misleading information or promotions, greater consistency and detail regarding patient record keeping, and who can and cannot perform cosmetic injectable treatments. Additionally, increased training requirements were established for certain staff who wish to carry out these treatments.

What is Schedule 4 cosmetic injectables Queensland compliance in practice?

In practice, Schedule 4 cosmetic injectables Queensland compliance refers to cosmetic injectables that are prescription-only medicines (S4). These S4 medicines are heavily regulated by the TGA, meaning they can only be ordered, received, stored, and prescribed by qualified individuals. They must only be prescribed by a medical practitioner or Nurse Practitioner after assessing the individual patient.

Additionally, administration duties must be carried out by appropriately authorised clinicians, such as registered nurses working under lawful direction. Clinics must also follow Queensland Health’s strict requirements for how medicines are ordered, stored, and recorded, and they must maintain accurate documentation of prescribing, stock movement, administration, and wastage to ensure full traceability of all injectable medicines used in the clinic.

Can RNs order or hold stock of cosmetic injectables in Queensland?

No, Registered Nurses cannot order or hold stock of cosmetic injectables in Queensland since the stricter guidelines came into effect in September 2025. This means that injectables such as Botox or other commonly used dermal fillers need to be purchased and stored by prescribers such as practitioners and Nurse Practitioners.

That said, RNs can be involved in administering injectables, but only when there is a valid prescription and they are working within appropriate clinical supervision and scope of practice. The reason for this is that Schedule 4 (prescription only) medicines are tightly controlled substances, and ordering authority is restricted to prescribers under Queensland medicines legislation.

What are the biggest AHPRA advertising compliance risks for cosmetic injectables?

When it comes to advertising, medi-aesthetic clinic owners need to take extra care when creating marketing content. The main risks come from how clinics communicate treatment services and outcomes with the public. Strict AHPRA guidelines restrict the usage of edited before and after images, the use of testimonials that refer to guarantees or outcomes, and anything that can mislead clients.

Clinics need to appoint someone to consistently review content before posting, implement staffing policies revolving around posting online, and carefully record and store information that can back up any claims made.

How often should a medi-aesthetic clinic run a compliance audit?

While there is no fixed legal requirement regarding how often clinics should run a compliance audit, in practice, many clinics implement a quarterly or annual audit. Clinics are legally responsible for ensuring ongoing compliance with AHPRA advertising rules, Queensland medicines legislation, and TGA advertising requirements at all times, so ongoing reviews are necessary.

These types of audits typically check documentation, patient consent, prescribing processes, Schedule 4 medicines handling, and advertising processes.

Staying compliant and patient-focused in 2026

For medi-aesthetic clinics in Queensland, staying compliant in 2026 extends far beyond meeting minimum regulatory requirements. Instead, the stricter guidelines implemented in September 2025 focus on patient consent, stricter advertising, greater patient safety, and the handling of S4 medicines (which include cosmetic injectables). Clinic owners are responsible for maintaining clear, detailed documentation, maintaining clear clinical oversight, and adhering to stricter advertising standards – all of which boil down to ensuring patient safety before, during, and after any treatments.

Compliance protects patients, strengthens business reputation, and enhances clinic continuity, which is important to understand. As highlighted through the guide, the September 2025 AHPRA guidance places great emphasis on accountability, evidence, and consistency, which is why it is important to conduct regular audits to stay compliant.

With that in mind, it is important to note that our compliance guide and checklist provide general information, not legal advice. It is always best to consult qualified professionals for your specific circumstances. In the meantime, our downloadable Medi-Aesthetic Compliance Checklist for Queensland can be used as a simple reference for what areas you need to review to stay compliant.

Compliance Checklist for Medi-Aesthetic Clinics in Queensland: 2026 Edition